ex entitlement, page-11

Hi Hawkeye

Clearly there are some (more) who would prefer to channel money to the company and who see value at the current SP. There will be an overhang but by how much I don't know.

I can't buy more than my entitlement (the cupboard is now bare) but it may be prudent for others (with funds) to keep their options open as news can always arive at the 11th hour.

It would be great if Maria could comment on the growing recognition (in the industry) of various midkine applications .... and where this must lead.

She could confirm Cellmid's support of the bone cancer research project. IMHO the indivative results bode well for the use of MK inhibitors to be used unilaterally or along side VEGF (and other) inhibitors.

Of critical importance in the near term is the level of satisfaction management has with intereste in our MK Elisa.

Ususally she prepares a presentation paper which should include the updates .... and this should prompt questions.

Hope someone remembers the coffee and biscuits!

cheers